- Home
- ROOT vs GYRE Comparison
ROOT vs GYRE Comparison
Compare ROOT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | GYRE |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 755.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROOT | GYRE |
|---|---|---|
| Price | $81.15 | $7.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $125.80 | $17.00 |
| AVG Volume (30 Days) | ★ 313.9K | 63.5K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.34 | 0.04 |
| Revenue | ★ $1,446,800,000.00 | $107,265,000.00 |
| Revenue This Year | $29.96 | $11.59 |
| Revenue Next Year | $5.89 | $26.31 |
| P/E Ratio | ★ $24.24 | $196.47 |
| Revenue Growth | ★ 38.50 | 2.13 |
| 52 Week Low | $68.08 | $6.11 |
| 52 Week High | $181.14 | $14.42 |
Technical Indicators
Market Signals| Indicator | ROOT | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 47.43 |
| Support Level | $78.96 | $7.36 |
| Resistance Level | $87.40 | $8.50 |
| Average True Range (ATR) | 3.51 | 0.35 |
| MACD | 0.71 | 0.02 |
| Stochastic Oscillator | 54.47 | 30.70 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.